MYC and medulloblastoma: At least four distinct subtypes comprise medulloblastoma: WNT-activated, SHH-activated, non-WNT/non-SHH group 3, and non-WNT/non-SHH group 4, with group 3 patients carrying c-Myc overexpression having the worst prognosis, as reflected in the current revision of the WHO classification [2–5].